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Rationale: Exposure to ozone causes a decrease in spirometric lung
function and an increase in airway inflammation in healthy young
adults at concentrations as low as 0.08 ppm, close to the National
Ambient Air Quality Standard for ground level ozone.
Objectives: To test whether airway effects occur below the current
ozone standard and if they are more pronounced in potentially
susceptible individuals, such as those deficient in the antioxidant
gene glutathione S-transferase mu 1 (GSTM1).
Methods: Pulmonary function and subjective symptoms were mea-
sured in 59 healthy young adults (19–35 yr) immediately before and
afterexposure to0.0 (clean air,CA) and0.06ppmozonefor 6.6hours
in a chamber while undergoing intermittent moderate exercise. The
polymorphonuclear neutrophil (PMN) influx was measured in 24
subjects 16 to 18 hours postexposure.
Measurements and Main Results: Subjects experienced a significantly
greater (P 5 0.008) change in FEV1 (6 SE) immediately after
exposure to 0.06 ppm ozone compared with CA (21.71 6 0.50%
vs. 20.002 6 0.46%). The decrement in FVC was also greater (P 5
0.02) after ozone versus CA (22.32 6 0.41% vs. 21.13 6 0.34%).
Similarly, changes in %PMN were greater after ozone (54.0 6 4.6%)
than CA (38.3 6 3.7%) exposure (P , 0.001). Symptom scores were
not different between ozone versus CA. There were no significant
differences in changes in FEV1, FVC, and %PMN between subjects
with GSTM1-positive and GSTM1-null genotypes.
Conclusions: Exposure of healthy young adults to 0.06 ppm ozone for
6.6 hours causes a significant decrement of FEV1 and an increase in
neutrophilic inflammation in the airways. GSTM1 genotype alone
appears to have no significant role in modifying the effects.
Keywords: pulmonary function; airway inflammation; polymorphism;
ozone exposure; exercise
Ozone is a major component of photochemical smog. Con-
trolled human exposure studies have been critical in demon-
strating that it can cause decrements in lung function (1–7) and
lung inflammation (8–11). Although the majority of these
studies involved exposures to relatively high (0.1–0.4 ppm)
concentrations for short periods of time (typically 2 h), pro-
longed exposure studies at lower levels were largely responsible
for the U.S. Environmental Protection Agency (EPA) lowering
the National Ambient Air Quality Standard for ground level
ozone in 2008. Several studies have now confirmed the initial
observation of Horstman and colleagues (4) that exposure of
healthy young adults to 0.08 ppm ozone for 6.6 hours while
undergoing intermittent moderate exercise will result in a sig-
nificant drop (5–8%) in FEV1 (5, 6). Similarly, studies using this
exposure regime demonstrated that 0.08 ppm ozone can initiate
inflammatory responses in the lungs of healthy young adults (9),
characterized by increases in polymorphonuclear neutrophils
(PMN) in bronchoalveolar lavage fluid collected 24 hours
postexposure. Recently, we have confirmed and extended these
findings in 15 healthy young adults by showing a significant
increase in sputum neutrophilic inflammation 18 hours post-
exposure to 0.08 ppm ozone (12).
Recent community-based air pollution studies using emer-
gency department records have reported associations for in-
creased risk of pediatric asthma at very low ozone concentrations
(13). This has led some to question whether adverse responses
could occur in healthy adults at concentrations below the cur-
rent standard. However, only two controlled human exposures
have investigated this and none to our knowledge have ad-
dressed inflammatory effects. Adams reported that healthy
young adults exposed to multiple ozone concentrations experi-
enced a significant decrease in lung function at 0.08 ppm but not
at 0.06 ppm or 0.04 ppm (7). However, a secondary analysis by
others of the same data concluded that 0.06 ppm may have
induced a change in FEV1 (14). In 2009, Schelegle and col-
leagues (15) reported that healthy young volunteers exposed to
step-wise ozone concentrations experienced a significant decre-
ment of FEV1 at concentrations as low as 0.07 ppm but not at
0.06 ppm.
Large heterogeneity in responses to ozone between individ-
uals has been reported (16, 17). Ozone exerts oxidant stress and
results in airway inflammation, and therefore genes that mod-
ulate inflammation and antioxidant defense mechanisms have
been proposed as potential effect modifiers. In particular,
glutathione S-transferase mu 1 (GSTM1) has attracted attention
as it is present in the airways, and gene deletions (GSTM1-null
genotype) can be present in up to 50% of the population,
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Inhalation of ozone causes decrements in lung function and
an increase in airway inflammation at concentrations near
the current Ambient Ozone Standard. It is not known what
the effects are at concentrations lower than this.
What This Study Adds to the Field
This study reports that acute exposure to ozone for 6.6
hours at a level of 0.06 ppm (a level below the current
Ambient Ozone Standard) causes significant effects on
pulmonary function and airway inflammation in healthy
young adults.
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resulting in complete absence of the enzyme. This polymor-
phism has been associated with reduced lung function (18, 19),
and numerous epidemiology and controlled exposure studies
have suggested that it may confer susceptibility to increased
airway inflammation to ozone as well as other oxidant air
pollutants (20, 21).
More than 100 million people in the United States now live
in the counties that do not meet the current ozone standard,
and public health consequences are enormous. In the present
study, we performed a randomized controlled human exposure
crossover study and investigated specifically if exposure of
healthy young adults to 0.06 ppm ozone for 6.6 hours with
exercise would cause measurable airway effects assessed by
pulmonary function (chosen a priori to be FEV1 and FVC) and
inflammatory markers (sputum PMN). We also examined if
responses were more pronounced in individuals with the
GSTM1-null genotype. Some of the preliminary results of




Fifty-nine healthy young adult subjects aged 19 to 35 years, with no
history of smoking in the past 2 years, completed the study. All subjects
underwent a screening procedure that included a complete medical
history and physical examination and a pregnancy test for females.
Exclusion criteria included respiratory illness or symptoms within 4
weeks or a positive pregnancy test. All subjects were genotyped for
GSTM1. The study protocol was approved by the Institutional Review
Board at the University of North Carolina Medical School in Chapel
Hill and the EPA, and informed consent was obtained from all subjects
before their participation in the study. Subject characteristics and
baseline lung function test values are shown in Table 1.
Study Design
The study design was similar to those used in previous studies (4, 7)
to facilitate comparison. Each subject was exposed to 0.00 ppm (clean
air, CA) and 0.06 ppm ozone for 6.6 hours with moderate exercise
in a stainless steel chamber (4 3 6 3 3.2 m). Exposures were ran-
domized, double-blinded, and separated by at least 1 week. Minute
ventilation (VE) was measured hourly and exercise levels adjusted to
VE 5 20 L/min/m2 body surface area to ensure that subjects breathed
consistently throughout exposure. Spirometric lung function and
symptom scores were assessed immediately before and after the 6.6-
hour exposure period. Sputum was collected the next morning approx-
imately 16 to 18 hours postexposure. Exposures were conducted only
during the cool weather season in Chapel Hill (November–March) to
minimize exposure to elevated ambient ozone.
Study Protocol
Training day. On a training day, all subjects were trained for lung function
measurements. Settings for the treadmill and bicycle ergometer required
to produce a desired value of VE was determined for each subject.
Exposure day. On the day of each exposure, subjects were assessed
for vital signs, completed a symptom questionnaire, and performed
preexposure lung function spirometry and body plethysmography
maneuvers. They then entered the chamber set for the appropriate
condition (CA or 0.06 ppm ozone) and began exercising for a 50-minute
period at 20 L/min/m2 body surface area in VE followed by a 10-minute
rest period. The exercise session was repeated six times alterna-
ting between the treadmill and bicycle with VE maintained within 6
2 L/min of the subject’s target value. Subjects were also given 35
minutes to eat lunch. Thus, they remained in the chamber for a total of
6.6 hours, during which ventilatory parameters (VE, VT, breathing
frequency) were measured and electrocardiac signals, heart rate, and
blood oxygen saturation monitored continuously to ensure subject
safety. Subjects were exposed in pairs (of the same sex). At the end of
exposure, spirometric and plethysmographic lung function measure-
ments were performed and a symptom questionnaire was obtained.
Follow-up day. On the next morning, subjects returned to the
laboratory and sputum samples were collected.
Measurements
Spirometry was performed on a 10.2-L dry seal digital spirometer
interfaced to a computer (SensorMedics Model 1022; SensorMedics;
Palm Springs, CA). At least three sets of qualified data were obtained
and the largest value selected for FEV1 and FVC as per American
Thoracic Society guidelines (23). Pulmonary function on all subjects
was measured using one dedicated spirometer and by one certified
pulmonary function technician to minimize variability. Specific airway
resistance (sRaw) was assessed by body plethysmography (Sensor-
Medics Model V6200) and the average of two highest values out of
three to five measurements obtained. Measurements were performed
before and immediately after exposure for use in endpoint analysis.
Additional spirometry measurements were performed in the chamber
during 10-minute rest periods primarily for monitoring subject safety
and were not necessarily performed by the same technician.
Symptoms were assessed before and after 6.6-hour exposure. The
subjects were asked to rate the severity of cough, pain on deep inspiration
(PDI), shortness of breath (SOB), and throat irritation on a five-point
scale ranging from 0 (none) to 4 (most severe). Subjects recorded the
severity score directly on the computerized questionnaire. Total symptom
severity was obtained by adding scores of all four symptoms.
GSTM1 genotypes were determined using real-time polymerase
chain reaction as previously described by Gilliland and colleagues (24)
from DNA isolated from white blood cells using the QIAamp DNA
Mini Kit (Qiagen Inc., Valencia, CA).
Sputum Collection and Analysis
Sputum samples were obtained and processed by the method described
by Alexis and colleagues (25). Briefly, subjects underwent sputum
TABLE 1. SUBJECT CHARACTERISTICS AND BASELINE LUNG FUNCTION MEASURES
All Subjects Males Females GSTM1-p GSTM1-n
No. 59 27 32 30 29
Age, yr 25.0 (0.5) 26.1 (0.9) 24.0 (0.5) 24.9 (0.8) 25.1 (0.7)
Height, cm 171.2 (1.2) 178.9 (1.2) 164.7 (1.0) 172.2 (1.5) 170.2 (1.9)
Weight, kg 70.5 (1.8) 78.8 (2.3) 63.4 (2.1) 71.5 (2.5) 69.4 (2.6)
BSA, m2 1.8 (0.03) 2.0 (0.03) 1.7 (0.03) 1.8 (0.04) 1.8 (0.04)
BMI, kg/m2 23.8 (0.48) 24.5 (0.72) 23.3 (0.64) 23.9 (0.68) 23.8 (0.69)
FEV1, L 4.02 (0.10) 4.64 (0.12) 3.49 (0.07) 4.14 (0.12) 3.89 (0.16)
FVC, L 4.83 (0.13) 5.69 (0.14) 4.10 (0.11) 4.94 (0.17) 4.72 (0.21)
FEV1/FVC, % 84.1 (0.8) 82.0 (1.1) 85.8 (1.2) 84.6 (1.2) 83.5 (1.2)
FEF25-75%, L/s 4.22 (0.14) 4.64 (0.23) 3.87 (0.14 4.39 (0.21) 4.05 (0.18)
FEFmax, L/s 9.03 (0.25) 10.61 (0.28) 7.69 (0.17) 9.49 (0.35) 8.54 (0.34)
Definition of abbreviations: BMI 5 body mass index; BSA 5 body surface area; FEF25-75% 5 forced expiratory flow between 25
and 75% of FVC; FEFmax 5 maximum forced expiratory flow; GSTM1-n 5 glutathione S-transferase mu 1 null; GSTM1-p 5
glutathione S-transferase mu 1 positive.
Values are mean (6 SEM)
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induction with hypertonic saline. Acquired samples were subjected
to plug selection and subsequent treatment with dithiothreitol. Cell
viability and total cell counts were evaluated and differential cell
counts examined (Hema-Stain3; Fisher Scientific). Acquired sputum
samples considered acceptable for processing had a minimum of 75 mg
of selected plug material, cell viability greater than 50%, and squamous
epithelial cells less than 40%. All sample processing and slide
preparations were performed on the same day of collection.
Ozone Generation and Monitoring
Ozone was generated by a silent electric discharge method (Model 502;
Meckenheim, Bonn, Germany) and introduced into the chamber that
was maintained at 22 6 1.08C and 40 6 5% relative humidity. The
concentration of ozone was continuously monitored using ultraviolet
photometric analyzers (TECO Model 49; Thermo Scientific, Franklin,
MA) that were periodically calibrated for 6 5% accuracy by NIST
traceable ozone calibrator (TECO Model 49PS).
Data and Statistical Analyses
The lung function endpoints were expressed as percent changes from
the preexposure (or baseline) values for each subject. Neutrophil
content in the sputum samples was expressed as percent of total cell
count (%PMN) and the measurements after each exposure were
compared. Linear mixed-effects models with a subject-specific random
intercept was used to test changes in response endpoints between clean
air and ozone exposures at the group level to account for subject-level
variability and repeated measures. The effect of GSTM1 and sepa-
rately sex was examined using a two-factor mixed-effects model with
repeated measures on a single factor, exposure and subject-level
random effects. We report the magnitude and direction of the expected
change along with its associated 95% equal two-tail confidence in-
tervals. R statistical software (Version 2.10.1) was used for the
analyses. a of 0.05 was used to determine statistical significance.
RESULTS
Exercise and Minute Ventilation
Means of six hourly measurements of VE, VT, breathing fre-
quency, and heart rate during 6.6-hour exposure to CA and ozone
are summarized in Table 2. Overall, there was no difference in
both ventilation parameters and heart rates between CA and
0.06 ppm ozone exposure.
Exposure to 0.06 ppm Ozone Causes Decrements
in Lung Function
The primary hypothesis tested in this study was that exposure to
0.06 ppm ozone would decrease FEV1 and FVC after 6.6 hours.
The results are summarized in Table 3. Exposure to ozone
resulted in a 1.71 6 0.50% (mean 6 SEM) decrease in FEV1
compared with virtually no change (0.002 6 0.46%) after
exposure to CA (Figure 1A). Thus, relative to CA, exposure
to 0.06 ppm ozone for 6.6 hours resulted in a 1.71 6 0.64%
decrement in FEV1 (P 5 0.008). These decrements did not
appear to be driven by a small subset of subjects (Figure 1B). Of
the 59 individuals studied, only three subjects showed greater
than 10% drop after ozone exposure. Similarly, FVC decreased
by 2.32 6 0.41% after ozone exposure versus 1.13 6 0.34% after
CA (Figure 1C). Ozone exposure thus caused a relative decre-
ment of 1.19 6 0.51% (P 5 0.02). Again, individual response to
ozone exposure was mostly within 6 5% change, as shown in
Figure 1D. Changes in other lung function parameters (forced
expiratory flow between 25% and 75% of FVC, maximum
forced expiratory flow, and sRaw) were not significant.
A second aim of the study was to determine the role of
GSTM1 in determining responses to ozone. Although both
genotypes had decrements in FEV1 after ozone exposure
relative to air, changes were only statistically significant for
GSTM1-positive subjects (Figure 2A). However, the difference
in FEV1 response between GSTM1-null and -positive subjects
was not statistically significant (P 5 0.72). Similarly, females
had a significant decrement in CA-adjusted FEV1 (1.93 6
0.88%, P 5 0.02), whereas males did not (1.45 6 0.95%, P 5
0.14), but the difference between sexes was not significant (P 5
0.66). No differences between GSTM1-null versus -positive and
males versus females were seen for FVC (Figure 2B).
Exposure to 0.06 ppm Ozone Causes
Pulmonary Inflammation
This study is the first to examine ozone concentrations below the
current standard to cause pulmonary inflammation. The results
are summarized in Table 4. Graphic illustration in Figure 3A
shows that ozone exposure alters the airway milieu as evidenced
by increases in %PMN in induced sputum samples. After air
exposure, %PMN averaged 38.3 6 3.7%. In contrast, ozone-
exposed samples averaged 54.0 6 4.6%. Thus, relative to clean
air, ozone exposure resulted in a 15.7 6 3.1% increase in %PMN
for the whole group (P , 0.002). Of the 24 subjects studied, all
but 5 subjects showed an ozone-induced increase in %PMNs and
10 showed greater than or equal to 20% increase (Figure 3B).
Figure 4 shows a significant increase in ozone-induced
%PMN for both GSTM1-null (20.0%; 95% CI, 11.0–29.0; P 5
0.001) and GSTM1-positive subjects (11.3%; 95% CI, 2.3–20.3;
P 5 0.02). Those carrying the null allele had a stronger response
(P 5 0.001) than those carrying the positive allele (P 5 0.02);
however, the estimate of the modifying effect of GSTM1 did not
reach significance (P 5 0.17; also see Table 4). Both males
(24.2%; 95% CI, 15.8–32.6; P 5 0.001) and females (8.5%; 95%
CI, 0.79–16.20; P 5 0.03) had statistically significant increases in
ozone-induced %PMNs. The modifying effect of sex was
significant (P 5 0.009). The changes in %PMN were not
accompanied by changes in total cell numbers for the whole
group or any subgroup after ozone versus air. Total cell counts
in sputum samples were 5.05 (6 0.82) 3 106 after CA and 6.93
(6 1.52) 3 106 after ozone (P 5 not significant [NS] vs. CA) for
the whole group.
Symptom Questionnaire
Of 56 subjects who had no symptoms at baseline, 20 subjects
reported symptoms after either CA or 0.06 ppm ozone exposure.
The most commonly reported symptom was throat irritation
followed by shortness of breath, pain on deep inspiration, and
cough. The mean (6 SEM) total symptom score was 0.43 6 0.11
for CA and 0.41 6 0.11 for ozone (P 5 NS versus CA). For
genotype subgroups, total symptom score was 0.40 6 0.16 for CA
and 0.47 6 0.17 for ozone in GSTM1-positive subjects and 0.46 6
0.16 for CA and 0.35 6 0.13 for ozone in GSTM1-null subjects
(P 5 NS versus CA for both groups). The score and nature of
the symptoms were similar between CA and ozone exposures.
DISCUSSION
In 2008 the EPA revised National Ambient Air Quality Standard
for ground level ozone down to 0.075 ppm (3-yr average of the
TABLE 2. BREATHING PARAMETERS AND HEART RATE
OF SUBJECTS DURING 6.6-HOUR EXPOSURE
VE (L/min) VT (L) F (min-1) Heart Rate (min-1)
Clean air 37.1 (0.2) 1.38 (0.05) 29.1 (0.9) 128.4 (1.1)
Ozone 36.5 (0.2) 1.37 (0.05) 29.0 (0.9) 127.0 (1.1)
Definition of abbreviations: F 5 breathing frequency.
Values are mean (6 SEM). Note that the target value of VE 5 20 L/min/m2. BSA
corresponds to unadjusted mean value of 36.5 L/min.
Kim, Alexis, Rappold, et al.: Effects of Ozone at 0.06 ppm Concentration 1217
fourth highest daily maximum 8-h average) (26). This was based
primarily on controlled human chamber studies of FEV1
changes postexposure after 6.6 hours. Inflammation of the
airway, as well as toxicology and epidemiology studies, were
used as supportive evidence. In this study, we demonstrate,
using the same exposure approach, decrements in FEV1 and
FVC at a concentration (0.06 ppm) below the current standard.
Furthermore, we demonstrate increased neutrophil airways
inflammation at this low ozone concentration.
To date, two previous studies have investigated lung function
at 0.06 ppm ozone using a 6.6-hour protocol; neither found
statistically significant effects (7, 15) even though their observed
effect size was greater than in our study. For example, they
reported clean air–adjusted FEV1 after 0.06 ppm ozone decre-
ments of 3.52 and 2.86%, whereas we observed a smaller drop
of 1.71%, yet our results were highly statistically significance
(P 5 0.008). Similarly, our reported change in FVC of 1.18%
was statistically significant (P 5 0.02), although in the range of
the 3.16 and 0.45% reported previously (7, 15). The key dif-
ference between the previous and the current study is that
although their studies were designed to compare multiple con-
centrations at multiple time points, ours was specifically de-
signed to limit the need for multiple comparisons.
To accomplish this, we used several strategies to increase the
statistical power and to minimize experimental variability. First,
our analysis was focused on only one ozone concentration and
TABLE 3. LUNG FUNCTION RESPONSES TO 6.6-HOUR EXPOSURE TO CLEAN AIR AND 0.06 PPM OZONE IN HEALTHY
YOUNG ADULTS
All Subjects Males Females GSTM1-p GSTM1-n
(n 5 59) (n 5 27) (n 5 32) (n 5 30) (n 5 29)
%D 95% CI %D 95% CI %D 95% CI %D 95% CI %D 95% CI
FEV1
CA 20.002 (0.46) 20.9, 0.9 0.59 (0.53) 20.5, 1.6 20.51 (0.72) 21.9, 0.9 20.08 (0.46) 21.0, 0.8 0.078 (0.82) 21.5, 1.7
Ozone 21.71 (0.50) 22.7, 20.8 20.86 (0.62) 22.1, 0.4 22.43 (0.74) 24.0, 21.1 22.07 (0.71) 23.5, 20.7 21.34 (0.69) 22.8, 20.1
Ozone-CA 21.71 (0.64)* 23.0, 20.5 21.45 (0.95) 23.4, 0.5 21.93 (0.88)* 23.8, 20.3 21.99 (0.90)* 24.0, 20.2 21.42 (0.92) 23.4, 0.3
FVC
CA 21.13 (0.34) 21.8, 20.5 20.77 (0.33) 21.4, 20.1 21.44 (0.56) 22.5, 20.3 21.11 (0.49) 22.1, 20.2 21.15 (0.48) 22.1, 20.2
Ozone 22.32 (0.41) 23.1, 21.5 21.26 (0.52) 22.3, 20.2 23.22 (0.57) 24.3, 22.1 22.41 (0.52) 23.4, 21.4 22.23 (0.65) 23.5, 21.0
Ozone-CA 1.19 (0.51)* 22.2, 20.2 20.49 (0.74) 22.0, 1.0 21.78 (0.68)* 23.1, 20.4 21.30 (0.73) 22.7, 0.1 21.07 (0.71) 22.5, 0.4
Definition of abbreviations: CA 5 clean air; CI 5 confidence interval; GSTM1-n 5 glutathione S-transferase mu 1 null; GSTM1-p 5 glutathione S-transferase mu 1
positive.
%D indicates change relative to preexposure, mean (6 SEM).































































































Figure 1. Percent changes in FEV1 and FVC after 6.6-hour
exposure to clean air and 0.06 ppm ozone. (A, B) Group
means (6 SEM) and individual changes, respectively, for
FEV1. (C, D) Group means (6 SEM) and individual changes,
respectively, for FVC.
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a comparison to clean air. Second, we enrolled nearly twice as
many subjects (n 5 59) as previous studies, as the study was
powered to examine the differences between two GSTM1
polymorphisms. Third, our analysis was determined a priori to
focus only on changes observed immediately postexposure for
lung function. Similarly, analysis of airway inflammation was
limited to %PMN 16 to 18 hours after exposure. Fourth, we
used only one dedicated pulmonary technician and spirometer
for primary lung function measurements. Last, our studies were
performed exclusively in the winter season, during which am-
bient ozone level was lower than 0.06 ppm (see Figure E1 in the
online supplement), and thus potential influence of prior
exposure to ambient ozone was minimized.
Our results may have significant public health implications.
Although most subjects (. 60%) showed less than 10% de-
crease in lung function after 0.06 ppm ozone, 3 of 59 subjects in
the present and 2 of 30 subjects in the Adams study (7) showed
a lung function decrement greater than 10%. This suggests
that 0.06 ppm ozone may cause lung function decrements in
the majority of young individuals with some 6% (e.g., 5 of 89
subjects) of them having a greater response. In addition, this is
the first study to examine and observe airway inflammatory
effects for ozone at concentration levels below 0.08 ppm.
Chronic airway inflammation may cause airway damage and
thereby bronchoconstriction and bronchial hyperresponsive-
ness. An increase in neutrophilic inflammation has been shown
to be strongly associated with exacerbation of airway disease
in people with asthma. Thus, ozone is uniquely associated with
worsening of asthma and increased hospitalization in children
with asthma (13). Although the current study is limited to
healthy subjects, the health consequences may be more severe
in individuals with preexisting diseases, particularly in asthma.
Effects of sex on response to ozone exposure have been re-
ported variably. Some studies found a greater response in FEV1
in female than in male subjects, whereas others found a compa-
rable response between them, mostly after a short-term exposure
to high-concentration ozone (27, 28). For a prolonged exposure
to low-concentration ozone, most studies report combined results
of both males and females with no specific analysis for sex effects
(6, 7, 15). The studies, however, appear to have assumed or found
no sex effects in pulmonary function response. In our study,
FEV1 and FVC decrement was not significant in males but was
significant in females; however, we found no significant difference
between males and females. In contrast, %PMN was increased
significantly in both sexes, with males showing a greater response
than females (P 5 0.009). Thus, it appears that ozone sensitivity
may differ between sexes depending on endpoints.
A two-factor mixed-effects model with repeated measures
was used to test if there was a difference in FEV1 responses
between GSTM1-positive and GSTM1-null subjects. We did not
find such an association in either FEV1 or FVC. This was
consistent with earlier studies (20, 29) that have shown no
independent role of GSTM1-null genotype on lung function
decrement. The role of GSTM1-null, however, may become
evident when it presents with other genotypes (NQO1 and
GSTP1) (19, 29). Regarding airway neutrophilia, although the







































































Figure 2. Clean air (CA) adjusted % changes (mean and 95%
confidence interval) in (A) FEV1 and (B) FVC after ozone exposure for
all subjects, and by sex and GSTM1 genotype. *P , 0.05; †0.05 , P ,
0.1. F 5 females; GSTM1-n 5 glutathione S-transferase mu 1 null;
GSTM1-p 5 glutathione S-transferase mu 1 positive; M 5 males; NS 5
not significant.
TABLE 4. POLYMORPHONUCLEAR NEUTROPHIL RESPONSES TO 6.6-HOUR EXPOSURE TO CLEAN AIR AND 0.06 PPM OZONE
IN HEALTHY YOUNG ADULTS
All Subjects Males Females GSTM1-p GSTM1-n
(n 5 24) (n 5 11) (n 5 13) (n 5 12) (n 5 12)
Mean (6 SEM) 95% CI Mean (6 SEM) 95% CI Mean (6 SEM) 95% CI Mean (6 SEM) 95% CI Mean (6 SEM) 95% CI
% Polymorphonuclear neutrophils
CA 38.3 (3.7) 31.1, 45.6 33.4 (5.3) 23.0, 43.8 42.4 (5.1) 32.4, 52.4 34.7 (5.6) 23.7, 45.7 41.9 (4.8) 32.5, 51.3
Ozone 54.0 (4.6) 45.0, 63.0 57.6 (6.4) 45.1, 70.1 50.9 (6.6) 38.0, 63.8 46.1 (6.7) 33.0, 59.2 61.9 (5.5) 51.1, 72.7
Ozone-CA 15.7 (3.1)* 9.6, 21.8 24.2 (4.3)* 15.8, 32.6 8.5 (3.7)* 0.79, 16.2 11.3 (4.5)* 2.3, 20.3 20.0 (4.6)* 11.0, 29.0
Total cell count
CA 5.05 3 106 (0.82) 4.08 3 106 (0.98) 5.86 3 106 (1.26) 3.97 3 106 (0.90) 6.13 3 106 (1.34)
Ozone 6.93 3 106 (1.52) 9.42 3 106 (3.03) 4.83 3 106 (0.96) 5.58 3 106 (2.23) 8.28 3 106 (2.10)
Definition of abbreviations: CA 5 clean air; CI 5 confidence interval; GSTM1-n 5 glutathione S-transferase mu 1 null; GSTM1-p 5 glutathione S-transferase mu 1
positive; PMN 5 polymorphonuclear neutrophils.
%PMN indicates polymorphonuclear neutrophils as % of total cell counts. SEM of total cell count is for the base number of 106.
* P , 0.05.
Kim, Alexis, Rappold, et al.: Effects of Ozone at 0.06 ppm Concentration 1219
difference was not significant, GSTM1-null subjects appeared to
have a greater neutrophilic inflammatory response than
GSTM1-positive subjects. A sample size estimate, however,
revealed that the nonsignificant increase would likely become
significant with a larger cohort of approximately 47 subjects,
which would be consistent with our earlier report on response of
GSTM1-null genotype to 0.4 ppm ozone (20). This seemingly
contradicting trend versus lung function response may be due to
differences in the putative modes of action of ozone. Although
changes in lung function are believed to occur via activation of
a subset of airway C-fibers (30), inflammation is believed to
originate from activation of nuclear factor-kB induced by
reactive oxygen species generation (31). Thus, corticosteroids
can blunt ozone-induced neutrophilia but not lung function
responses (32). GSTM1 is believed to act by reducing oxidative
stress, including detoxification of byproducts generated by
inflammation. In line with previous studies (33), we found no
relationship between lung function and inflammation.
In summary, our study shows ozone effects on two indepen-
dent markers of airway health at a level as low as 0.06 ppm in
healthy young adults. We did not find a significant role of GSTM1
genotype alone on the ozone-induced airway effects, but there
may be individuals or subpopulations with enhanced sensitivity
(such as in asthma) at these levels. We therefore conclude that
exposure to ozone levels below the current standard can cause
changes in lung function and initiate an airway inflammatory
response in a young adult population and pose a health risk, par-
ticularly to susceptible populations.
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Figure 3. % Polymorphonuclear neutrophils (PMN)
changes in sputum samples after 6.6-hour exposure to
clean air (CA) and 0.06 ppm ozone for (A) the group
mean, and (B) each individual. Error bars represent
standard error. %PMN is defined by neutrophil num-
ber as % of total cell counts in the sample. F 5 females;
GSTM1-n 5 glutathione S-transferase mu 1 null;
GSTM1-p 5 glutathione S-transferase mu 1 positive;
M 5 males; NS 5 not significant.






































Figure 4. Clean air (CA) adjusted % changes in polymorphonuclear
neutrophils (PMN) (mean and 95% confidence interval) after ozone
exposure for all subjects, and by sex and GSTM1 genotype. *P , 0.05.
F 5 females; GSTM1-n 5 glutathione S-transferase mu 1 null; GSTM1-
p 5 glutathione S-transferase mu 1 positive; M 5 males; NS 5 not
significant.
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